SWX:NOVNPharmaceuticals
Novartis Readies Key Cancer Data As AI And Rare Disease Work Grow
Novartis (SWX:NOVN) plans to present extensive new data on late-stage cancer and immune disease therapies, including Pluvicto, Kisqali, Scemblix and ianalumab, at the 2026 ASCO and EHA congresses.
The company is progressing treatments for rare conditions such as Charcot–Marie–Tooth disease alongside its broader oncology and hematology pipeline.
Novartis is also participating in a major AI industry summit, highlighting its focus on digital tools across research and development.
For investors...